About Carmot Therapeutics
Carmot Therapeutics is a private company based in Berkeley, California. It has reported $349,799,919 raised in six offerings on Form D since April 2010. Its chief executive is Heather Turner.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 24, 2023 | Jun 6, 2023 | $149,999,802fully sold | 25 | $5.9M | EquityRule 506(b) | Form D ↗ |
| Jul 25, 2022 | Aug 8, 2022 | $160,671,809fully sold | 15 | $10.7M | EquityRule 506(b) | Form D ↗ |
| Sep 17, 2020 | Oct 1, 2020 | $26,282,207of $46.8M target | 6 | $4.3M | EquityRule 506(b) | Form D ↗ |
| Aug 11, 2017 | Aug 25, 2017 | $10,795,943of $15.3M target | 4 | $2.6M | EquityRule 506(b) | Form D ↗ |
| Jun 28, 2012 | Jul 17, 2012 | $500,159of $1.2M target | 2 | $250K | Equity06 | Form D ↗ |
| Apr 7, 2010 | Apr 23, 2010 | $1,549,999fully sold | 2 | $774K | Equity06 | Form D ↗ |
| Total, six offerings | $349,799,919 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Carmot Therapeutics's Form D filed Jun 6, 2023.
Earlier filings also listed Stig Hansen (chief executive officer and director, last listed Aug 2022), Tim Kutzky (director, last listed Oct 2020), Larry Lasky (director, last listed Aug 2017), Daniel Erlanson (executive officer and director, last listed Aug 2017), David Goeddel (director, last listed Jul 2012) and Magnus Persson (director, last listed Apr 2010).